Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Hepatocellular Carcinoma · Obesity

Hospital Authority

Hospital Authority, Hong Kong

Hospital Authority clinical programs — 61 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN HQ
1991 Founded
12,669 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
Founded
1991
Employees
12,669
Programs
322
Drugs
301
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Hospital Authority projects

61 ClinicalTrials.gov programs sponsored by Hospital Authority.

Hospital Authority has 61 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

61 programs

Clinical programs

Page 1 of 2

  1. 1 apical pleurectomy

    Hospital Authority, Hong Kong

    Pneumothorax

    phase 3 other active

    1 trial

  2. AST-120and pentoxyphylline (PTX)

    Hospital Authority, Hong Kong

    Acute Kidney Injury

    phase 3 small molecule active

    1 trial

  3. Autologous Peripheral Blood Stem Cell injection

    Hospital Authority, Hong Kong

    Acute Myocardial Infarction

    phase 3 mab active

    1 trial

  4. Bacillus Calmette Guerin and interferon alpha

    Hospital Authority, Hong Kong

    Carcinoma of Urinary Bladder, Superficial

    phase 3 small molecule completed

    1 trial

  5. Barley beta-glucan(3.0g)

    Hospital Authority, Hong Kong

    Overweight; Hyperlipidemia

    phase 3 other completed

    1 trial

  6. Bevacizumab

    Hospital Authority, Hong Kong

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  7. Bortezomib

    Hospital Authority, Hong Kong

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  8. Botulinum toxin type A

    Hospital Authority, Hong Kong

    Obesity

    phase 3 small molecule active

    1 trial

  9. Cannabidiol Oil

    Hospital Authority, Hong Kong

    Dementia, Vascular

    phase 3 small molecule active

    1 trial

  10. Capecitabine plus temozolamide

    Hospital Authority, Hong Kong

    Neuroendocrine Neoplasia's (NENs)

    phase 3 small molecule active

    1 trial

  11. Champix

    Hospital Authority, Hong Kong

    Tobacco Use Disorder

    phase 3 small molecule completed

    1 trial

  12. Control

    Hospital Authority, Hong Kong

    Hallucinations, Verbal Auditory

    phase 3 small molecule active

    1 trial

  13. DAC-HAAG-02

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  14. Dexmedetomidine Hcl 100 Mcg/mL Inj

    Hospital Authority, Hong Kong

    Congenital Heart Disease in Children

    phase 3 small molecule completed

    1 trial

  15. Dienogest

    Hospital Authority, Hong Kong

    Endometriosis

    phase 3 small molecule active

    1 trial

  16. Doxycycline

    Hospital Authority, Hong Kong

    Tuberculosis

    phase 3 small molecule active

    1 trial

  17. Empagliflozin 10 MG

    Hospital Authority, Hong Kong

    Diabetic Nephropathies

    phase 3 small molecule terminated

    1 trial

  18. Eriobotyra Japonica Lindley Extract

    Hospital Authority, Hong Kong

    Cognitive Function

    phase 3 other completed

    1 trial

  19. Flublok Quadrivalent vaccine

    Hospital Authority, Hong Kong

    Influenza Vaccination

    phase 3 mab completed

    1 trial

  20. Formosa 1-Breath Free (NRICM101)

    Hospital Authority, Hong Kong

    Influenza Viral Infections

    phase 3 small molecule active

    1 trial

  21. Fractional CO2 Laser

    Hospital Authority, Hong Kong

    Treatments of Striae Gravidarum

    phase 3 other active

    1 trial

  22. GCSF

    Hospital Authority, Hong Kong

    End Stage Liver Disease

    phase 3 small molecule active

    1 trial

  23. Intravenous methylene blue administration

    Hospital Authority, Hong Kong

    Severe Sepsis

    phase 3 small molecule active

    1 trial

  24. Intravenous thrombolysis plus tirofiban

    Hospital Authority, Hong Kong

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  25. L-alanyl-L-glutamine dipeptide

    Hospital Authority, Hong Kong

    Coronary Artery Bypass

    phase 3 small molecule completed

    1 trial

  26. LC-1000

    Hospital Authority, Hong Kong

    Coronary Artery Disease

    phase 3 other completed

    1 trial

  27. Microfracture

    Hospital Authority, Hong Kong

    Other Articular Cartilage Disorders

    phase 3 other active

    1 trial

  28. Mifepristone

    Hospital Authority, Hong Kong

    Miscarriage

    phase 3 small molecule completed

    1 trial

  29. Online HDF

    Hospital Authority, Hong Kong

    End Stage Renal Disease

    phase 3 other completed

    1 trial

  30. Oral dexamethasone

    Hospital Authority, Hong Kong

    Bronchiolitis

    phase 3 small molecule completed

    1 trial

  31. Oral immunonutrition

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 3 other active

    1 trial

  32. PBSCs

    Hospital Authority, Hong Kong

    Hematological Malignancies

    phase 3 other completed

    1 trial

  33. PEG-interferon-Alfa-2A

    Hospital Authority, Hong Kong

    Chronic Hepatitis B

    phase 3 small molecule active

    1 trial

  34. Pantoprazole (Pantoloc)

    Hospital Authority, Hong Kong

    Peptic Ulcers

    phase 3 small molecule active

    1 trial

  35. Pemetrexed 500mg/m2 iv

    Hospital Authority, Hong Kong

    NSCLC

    phase 3 small molecule active

    1 trial

  36. Placebo

    Hospital Authority, Hong Kong

    Congenital Heart Disease in Children

    phase 3 small molecule completed

    1 trial

  37. Platelet Rich Plasma

    Hospital Authority, Hong Kong

    Severe Oligoasthenoteratozoospermia

    phase 3 mab completed

    1 trial

  38. Progesterone supplementation

    Hospital Authority, Hong Kong

    Assisted Reproductive Technology

    phase 3 other active

    1 trial

  39. Rifaximin

    Hospital Authority, Hong Kong

    Decompensated Cirrhosis

    phase 3 small molecule terminated

    1 trial

  40. Rituximab

    Hospital Authority, Hong Kong

    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    phase 3 mab completed

    1 trial

  41. Sodium tetradecyl sulfate

    Hospital Authority, Hong Kong

    Gastric Varices Bleeding

    phase 3 small molecule active

    1 trial

  42. TCHIRB-970208-E

    Hospital Authority, Hong Kong

    Menopausal Women

    phase 3 small molecule active

    1 trial

  43. Tacrolimus

    Hospital Authority, Hong Kong

    Graft vs Host Disease

    phase 3 small molecule completed

    1 trial

  44. Taping and Sham Taping

    Hospital Authority, Hong Kong

    Stroke

    phase 3 other completed

    1 trial

  45. Taxotere , Epirubicin

    Hospital Authority, Hong Kong

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  46. Tenecteplase

    Hospital Authority, Hong Kong

    Ischemic Stroke

    phase 3 small molecule active

    1 trial

  47. Terazosin

    Hospital Authority, Hong Kong

    Stent Related Symptoms

    phase 3 small molecule active

    1 trial

  48. Vitamin D3

    Hospital Authority, Hong Kong

    Lupus Erythematosus, Systemic

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Hospital Authority have?

61 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.